Morgan Stanley Innate Pharma Sa Put Options Transaction History
Morgan Stanley
- $1.39 Trillion
- Q4 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding IPHA
# of Institutions
11Shares Held
142KCall Options Held
0Put Options Held
0-
Exchange Traded Concepts, LLC77.4KShares$146,9650.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il11.9KShares$22,5200.0% of portfolio
-
Gamma Investing LLC Foster City, CA3.98KShares$7,5520.01% of portfolio
-
Ubs Group Ag3.51KShares$6,6690.0% of portfolio
-
Rhumbline Advisers Boston, MA675Shares$1,2820.0% of portfolio
About Innate Pharma SA
- Ticker IPHA
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 79,893,000
- Market Cap $152M
- Description
- Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and periphera...